



NEWS RELEASE

# Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

2025-06-12

HOLON, Israel, June 12, 2025 /PRNewswire/ -- **Compugen Ltd.** (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the presentation of AI/ML driven predictive computational research at upcoming international scientific conferences reflecting Compugen's scientific capabilities in understanding complex cancer biology.

## Poster details:

**Conference:** 2025 Annual Congress of the European Association for Cancer Research, June 16-19 Lisbon, Portugal

**Poster number:** EACR25-3113

**Title:** Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypes

**Presenting author:** Amir Toporik, Computational Discovery, Compugen

**Date of presentation:** June 18, 2025

**Conference:** International Society for Computational Biology and European Conference on Computational Biology- Annual International Conference on Intelligent Systems for Molecular Biology, July 20-24, 2025, Liverpool, UK

**Poster number:** 947

**Title:** Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanisms

**Presenting author:** Itamar Borukhov, Ph.D., Computational Discovery, Compugen

Posters will be available in the publications section of Compugen's website, [www.cgen.com](http://www.cgen.com), following presentation.

## About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

## Company contact:

Yvonne Naughton, Ph.D.

Head of Investor Relations and Corporate Communications

Email: [ir@cgen.com](mailto:ir@cgen.com)

Tel: +1 (628) 241-0071

View original content: <https://www.prnewswire.com/news-releases/compugen-to-present-aiml-driven-predictive-computational-research-at-upcoming-international-scientific-conferences-302480072.html>

SOURCE Compugen Ltd.